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Durability and Long-Term Performance*Patrizio Lancellotti, MD, PHD,a,b Christophe Martinez, MD,a Marc Radermecker, MD, PHDaT ranscatheter aortic valve replacement(TAVR) is an established treatment optionfor patients with symptomatic severe aortic
stenosis who are at intermediate to high/prohibitive
surgical risk (1). TAVR is noninferior to surgical aortic
valve replacement (SAVR) in terms of early and
mid-term mortality and is likely to be superior if the
transfemoral approach is used (2). In the real world,
the countdown has already started for extending the
use of TAVR to patients who are at low surgical risk.
Several large randomized trials to examine the value
of TAVR versus SAVR in younger patients without
major comorbidities are ongoing. To date, the only
published randomized trial in low-risk patients is
NOTION (Nordic Aortic Valve Intervention Trial)
(NCT01057173). In this study, 280 patients (82% of
whom were low risk, Society of Thoracic Surgeons
score <4%) were randomized 1:1 to TAVR (CoreValve
self-expanding bioprosthesis, Medtronic, Minneapo-
lis, Minnesota) or SAVR. There was no signiﬁcant
difference in the primary endpoint of all-cause mor-
tality, stroke, or myocardial infarction at 2 years
(15.8% vs. 18.8%) (3).
STRUCTURAL VALVE DETERIORATION
Valve durability remains the crux of discussion as the
target population for TAVR evolves to includeISSN 0735-1097/$36.00
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disclose.younger, low-risk patients (80% of patients with
aortic stenosis undergoing surgery) who are likely to
survive for a number of years after the procedure. The
biological tissue from both surgical and transcatheter
bioprostheses is prone to structural valve deteriora-
tion (SVD), which could lead to hemodynamic valve
dysfunction (stenosis, regurgitation, or both) and
development of symptoms (4). Durability is deter-
mined by numerous physical (e.g., tissue character-
istics, anticalciﬁcation treatments, leaﬂet and valve
design, and transvalvular gradients) and clinical fac-
tors (e.g., patient age and various metabolic abnor-
malities) (4). Reported rates of SVD are highly
variable, depending on the deﬁnition and type of
valve used. In most SAVR series, SVD was established
on the basis of reoperation for bioprosthetic valve
failure (BVF), referring to its clinical consequences
rather than to new onset or worsening of morpho-
logical/functional abnormalities of the bioprosthesis
(4). In fact, SVD is usually a progressive process, with
gradual changes in hemodynamic valve performance
and severity over time. Various stages of SVD can be
highlighted, with morphological changes preceding
the advent of hemodynamic deteriorations (5). These
considerations have been differently expressed in
recent consensus statements. Overall, 4 nosological
entities characterize the term bioprosthetic valve
dysfunction and may be responsible for BVF: SVD
(leaﬂet ﬁbrosis, calciﬁcation, tear, pannus formation),
non-SVD (paravalvular leak, prosthesis malposition,
late embolization), thrombosis, and endocarditis
(Figure 1). As a point of criticism of the recent Euro-
pean consensus deﬁnition of bioprosthetic valve
dysfunction, patient-prosthesis mismatch (PPM) is
neither a deterioration nor a dysfunction, but de-
scribes the use of a prosthesis of a given type that is
functioning normally but is too small for a patient of a
given size (5). Therefore, it may warrant a separatehttps://doi.org/10.1016/j.jacc.2018.11.043










• Too small prosthesis in
   relation to patient’s
   body size
• Onset/worsening symptom
• Valve-related death
• Aortic valve re-intervention
• New MPG ≥20 mm Hg + ↓EOA + ↓DVI
• MPG ≥10 mm Hg change from baseline
  + ↓EOA + ↓DVI
• New or worsening intraprosthetic








• Late prosthesis migration
• Late prosthesis embolization
A B
(A) Severe increase in mean pressure gradient; (B) severe intraprosthetic regurgitation. DVI ¼ Doppler velocity index; EOA ¼ effective oriﬁce
area; MPG ¼ mean pressure gradient.
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555entity, just like thrombosis and endocarditis,
although it is not considered reversible.
SAVR AND LONG-TERM PERFORMANCE
Previously, in the absence of a standardized deﬁni-
tion of SVD, there were several barriers to comparing
the durability of speciﬁc bioprosthetic valves. Most
comparative studies were observational rather than
randomized, with wide variability in patient man-
agement and follow-up. Meta-analyses including
porcine and pericardial aortic bioprostheses showed
that SVD commonly begins 8 years after implantation,
with a much higher SVD rate after 10 years (6,7).
Pibarot et al. (8) reported overall freedom from rein-
tervention or death in surgical valves of 95% of
patients at 5 years, 70% to 90% at 10 years, and 50%
to 80% at 15 years. Other studies also conﬁrmed
excellent long-term results, with BVF ﬂuctuating
between 10% and 20% in a 10-year period (4).
Nevertheless, when both morphological and hemo-
dynamic valve deterioration using Doppler echocar-
diography are considered, the rates of bioprostheticvalve dysfunction are substantially higher (10% to
30% at 5 to 10 years post-SAVR) (9).
TAVR DURABILITY:
WHEN THE DEFINITION OF SVD MATTERS!
In the ﬁeld of TAVR, data on durability are currently
very limited. Toggweiler et al. (10) reported favorable
5-year outcomes with excellent hemodynamics and
signs of moderate prosthetic valve failure observed in
only 3.4% of the 88 patients receiving a ﬁrst-
generation Sapien valve (Edwards Lifesciences,
Irvine, California). No patient developed severe
valvular regurgitation or stenosis. Subsequently, Dvir
(11) reported a worrying incidence of degeneration in
378 patients receiving Cribier-Edwards, Edwards
Sapien, or Sapien XT valves (Edwards Lifesciences),
with up to 50% SVD within 8 years after implantation,
generating concern among the structural heart com-
munity regarding the durability of TAVR prostheses.
The investigators also noted gradually increasing
calciﬁcation in the TAVR valve that progressed to
valve degeneration within the ﬁrst 5 years, with a
SEE PAGES 537 AND 546
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556steep increase in valve degeneration after 5 years.
Degeneration was deﬁned in this analysis as moder-
ate regurgitation (intravalvular and paravalvular)
and/or a mean gradient $20 mm Hg not present at
30 days post-procedure that has clearly contributed
to the overestimation of SVD incidence. In the deﬁ-
nition of SVD proposed in the European position
statement (5), paravalvular regurgitation belongs to
non-SVD, whereas moderate SVD is deﬁned as a mean
gradient $20 mm Hg and/or an increase in mean
gradient $10 mm Hg during follow-up and/or new
onset or worsening of transprosthetic regurgitation
with a ﬁnal moderate regurgitation grade. Severe SVD
is deﬁned as mean gradient $40 mm Hg and/or an
increase in mean gradient $20 mm Hg during follow-
up and/or new onset or worsening of transprosthetic
regurgitation and ﬁnal severe regurgitation grade.
Using this new European deﬁnition, Eltchaninoff
et al. (12) reported a 3.2% incidence of SVD and a
0.58% incidence of BVF at 8 years in 378 patients.
Holy et al. (13) also reported excellent valve perfor-
mance, with no severe SVD at 8 years of follow-up. All
this is in line with recent data from TAVR pivotal
randomized control trials and large-scale registries
demonstrating reassuring durability data, with low
rates of SVD at 6 to 8 years of follow-up, regardless of
the valve type (2,14,15).
TAVR AND LONG-TERM DURABILITY:
NEW EVIDENCE
In this issue of the Journal, 2 studies have brought out
new evidence about TAVR and long-term durability.
First, Blackman et al. (16) reported excellent valve
performance with low incidence of hemodynamic
SVD 5 to 10 years post-procedure in the UK TAVI
Registry. Moderate SVD was noted in 8.7% of the
study population (regurgitation in 57%, stenosis in
43%), whereas severe SVD (1 with CoreValve, 0 with
Edwards) was observed in 0.4% of the study popula-
tion. No patients developed non-SVD during follow-
up. Therefore, it would not be unjustiﬁed to
conclude that TAVR appears durable in these elderly
patients who were at increased risk for surgery.
Morphological SVD and clinically overt forms of BVF
were, however, not reported, and only a small portion
(241 patients were alive at follow-up, with CoreValve
in 150 and Edwards valve in 80) of the entire registry
population (N >1,500), for which echocardiographic
data were available both at baseline and >5 years, was
analyzed. Median follow-up was only 5.8 years,
with <15% having follow-up beyond 8 years.
Numbers of patients at risk beyond 5 years were,
however, relatively reasonable (68 at 6 years) whencompared with previous registries. Intriguingly, there
was a progressive decrease in peak gradient and in
the degree of regurgitation from mild to none/trivial
from baseline to follow-up in the CoreValve group.
Although of interest, these data should be interpreted
with caution and considered hypothesis-generating
only.Second, Søndergaard et al. (17) have also signiﬁ-
cantly contributed to further enriching our knowl-
edge about TAVR durability. Using data from the
NOTION randomized study cohort to compare rates of
SVD and BVF (valve durability deﬁned according to
current European standardized deﬁnitions), the in-
vestigators reported sustained clinical outcomes 6
years after self-expandable CoreValve implantation.
All-cause mortality at 6-year follow-up was similar in
both groups (TAVR 42.5% vs. SAVR 37.7%), but rates
of moderate to severe SVD were signiﬁcantly higher
after surgery (24.0% vs. 4.8%), whereas rates of non-
SVD, endocarditis (5.9% vs. 5.8%), and BVF (6.7% vs.
7.5%) did not differ according to the mode of inter-
vention. Notably, the effective oriﬁce area was
signiﬁcantly greater for TAVR than for SAVR at all
timepoints post-procedure, with an area of 1.53 cm2
versus 1.16 cm2 for surgical valves at 6 years. No cases
of clinical thrombosis were noted in either group, but
computed tomography scans were not used to detect
subclinical thrombosis. Although the overall results
of the NOTION trial are promising, the trial is likely
underpowered because there were only 50 TAVR and
50 SAVR patients with 6 years of data available. The
echocardiographic measurements were not adjudi-
cated by an echocardiography core lab, and TAVR was
performed exclusively using the self-expanding ﬁrst-
generation CoreValve device. Whether similar results
could be obtained with other devices (notably,
balloon-expandable systems and more recent second-
and third-generation self-expanding devices) needs
to be addressed.
Signiﬁcantly, both the NOTION trial and the TAVI
UK registry deﬁned SVD as a combination of genuine
SVD and PPM (mean gradient $20 mm Hg at base-
line), which overestimates the true incidence of SVD,
especially in the subset of patients with a higher
prevalence of PPM (e.g., SAVR, valve-in-valve).
Indeed, with the European deﬁnition, a patient
harboring a mean gradient $20 mm Hg due to PPM
would be considered as having SVD even if there were
no signiﬁcant valve hemodynamic deterioration dur-
ing follow-up (e.g., mean gradient of 22 mm Hg at
1 month and 21 mm Hg at 7 years, or 18 mm Hg at
1 month and 21 mm Hg at 5 years). Given that the
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557prevalence of PPM is higher in SAVR than in TAVR,
the use of this deﬁnition may bias the comparison of
SVD incidence in favor of TAVR. As a matter of fact, in
the NOTION trial, the higher rate of SVD was mainly
driven by the mean gradient $20 mm Hg criterion:
22.2% versus 2.9%. With the increase in mean
gradient $10 mm Hg criterion from the 3-month
echocardiogram, a more robust criterion for SVD,
the SVD rates were 11.1% versus 1.4%. Hence, the true
incidence of SVD in the NOTION trial as well as in UK
TAVI was likely much (w2-fold) lower than reported.
Nevertheless, even with the more restrictive and
robust criteria for SVD based on valve hemodynamic
deterioration during follow-up, the rates of SVD
remained signiﬁcantly higher in SAVR versus TAVR
(moderate: 11% vs. 1.4%; and severe: 3% vs. 0.7%),
which is an interesting and encouraging testimony to
TAVR durability. This also indirectly raises the issue
of the link between PPM and early SVD. PPM is
facilitated through increased hemodynamic stress on
the deteriorating leaﬂet valve, as demonstrated in a
large SAVR cohort (18). Lower incidence of PPM in
TAVR may delay SVD compared with SAVR, as the
present data imply. The rate of SVD using the hemo-
dynamic deterioration criterion (i.e., an increase in
gradient $10 mm Hg) but excluding the criterion of a
mean gradient $20 mm Hg (at any follow-up echo-
cardiogram) was actually similar in the NOTION trial
for SAVR (11%) versus that (13.4% at 5 years) reportedrecently by Salaun et al. (19) in a single-center study
including 1,387 patients who underwent SAVR.
Therefore, there is a need to further reﬁne the stan-
dardized deﬁnitions of SVD recently proposed in the
published data (5). Finally, in the NOTION trial, the
similar incidence of BVF, despite a much higher
incidence of SVD in SAVR versus TAVR, may be
explained by the fact that the vast majority of SVD
were moderate, with likely no or minimal clinical
impact, at least in the short term.
Although data from the NOTION trial and the UK
TAVI registry are very reassuring, further long-term
studies are warranted, particularly with respect to
the desire to extend the indications of TAVR to
young, low-risk patients. In fact, heeding the expe-
rience with surgical SVD (usually not seen until 5 to 10
years post-procedure) and the inverse relationship
between age at SAVR and subsequent SVD, more time
would be needed to accurately assess long-term valve
durability and to understand the mechanism of po-
tential BVF, which, in turn, will enable us to devise
preventive strategies.
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